Multiple Myeloma Clinical Trial

Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

Summary

This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and carfilzomib. We hypothesize that the addition of carfilzomib to a conditioning regimen of melphalan and bendamustine in the setting of autologous transplantation for multiple myeloma is feasible and safe.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of multiple myeloma
At least 2 x 106 CD34+ cells/kg have been collected from the patient and cryopreserved for ASCT
Greater than 18 years
Karnofsky score greater than 70%
No evidence of progressive bacterial, viral, or fungal infection
Absolute neutrophil count above 1000
Platelet count above 50,000
Hemoglobin above 8 g/dL
Creatinine clearance greater than 50 mL/min
Total bilirubin, ALT, and AST less than 2 x the upper limit of normal
Alkaline phosphatase less than or equal to 250 IU/L
Left Ventricular Ejection Fraction (LVEF) greater than or equal to 45%
Adjusted Carbon Monoxide Diffusing Capacity (DLCO) greater than or equal to 60%
Negative HIV serology
Recovered from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and hematological toxicity)
Patients with a pre-transplant disease status consistent with a very good partial response (VGPR), partial response (PR), stable disease (SD), progressive disease (PD), or relapse from complete remission (CR).

Exclusion Criteria:

Patients who are refractory to carfilzomib. Refractory is defined as disease progression while on carfilzomib therapy after receiving at least two cycles of treatment.
Patients with a complete response (CR) (including near CR and stringent CR) to conventional induction therapy and proceeding to transplantation.
Pregnant or nursing females or women of reproductive capability who are unwilling to use effective contraception. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been post-menopausal (stopped menstrual periods) for more than 24 months in a row.
Male subjects who refuse to practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (ie, post-vasectomy).
Patient with Grade 2 peripheral neuropathy
Inability to provide informed consent
Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.
Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments.
Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Diagnosed or treated for another malignancy within 3 years of enrollment (with the exception of non-melanoma skin cancer).
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.
Prisoner

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

18

Study ID:

NCT02148913

Recruitment Status:

Completed

Sponsor:

Spectrum Health Hospitals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Spectrum Health
Grand Rapids Michigan, 49503, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

18

Study ID:

NCT02148913

Recruitment Status:

Completed

Sponsor:


Spectrum Health Hospitals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider